Hepatocellular Carcinoma (HCC) is the sixth most common cancer worldwide in terms of number of cases and the second major contributor to cancer mortality in man. The survival rates in the United States and developed countries are only 3% to 5%[@b1][@b2]. There are still no effective biomarkers for the early diagnosis and prognosis of HCC. Currently, only about 30% to 40% patients with HCC can get effective treatment at the right time[@b3]. It is extremely necessary to discover new biomarkers for precision diagnosis, prognosis and treatment of HCC.

MicroRNAs (miRNAs) are small endogenous non-coding RNAs with 22--24 nucleotides in length. They play important roles in regulating human genes by inhibiting translation or cleavage. Recent studies showed that miRNAs were associated with a variety of important biological processes such as cell proliferation, development, and apoptosis[@b4][@b5]. Accumulating evidence indicated that miRNAs could be latent biomarkers in human cancers, including gastric cancer, lung cancer, prostate cancer, and breast cancer etc.[@b6][@b7][@b8][@b9]. Nowadays, extensive research efforts have demonstrated the biomarker role of miRNAs in HCC. For example, Jiang and his colleagues confirmed that miRNA panel assay (miR-10b, miR-106b and miR-181a) could be potential biomarkers for HCC preliminary screening[@b10]. He *et al*. focused on the applications of miRNAs from 13 studies and 21 sets of data and the association between the risk of HCC and miRNAs polymorphisms[@b11]. Another review summarized the function of circulating miRNAs[@b12], and a meta-analysis included 14 studies involving 1,848 cases with HCC and 1187 controls concluded that the miRNA panels can be biomarkers for HCC with AUC = 0.99 (96% sensitivity and 96% specificity)[@b13]. Many comprehensive reviews recommend to pay attentions to the role and function of miRNAs in disease diagnosis, prognosis and therapy[@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22]. However, the differences in biological features of miRNAs between blood and tissues are still unclear, which limits the investigation on understanding clinical implications of miRNAs in different specimen.

In this review, we performed comprehensive functional analyses and comparisons of miRNA biomarkers in blood and tissues. The miRNA biomarkers in "tissues" were mainly extracted from liver tissues, adjacent noncancerous tissues or human HCC tissues whereas those in "blood" were collected from plasma, serum or whole blood samples. This review aims at comprehensively understanding the pathogenic mechanism and clinical value of HCC biomarker miRNAs, and providing insights into precision diagnosis and treatment of HCC.

Methods
=======

Data collection
---------------

We systematically collected HCC biomarker miRNAs from citations in NCBI PubMed by retrieval formula "(liver cancer\[tiab\] OR intrahepatic bile duct\[tiab\] OR hepatocellular carcinoma\[tiab\] OR hepatoblastoma\[tiab\] OR cholangiocarcinoma\[tiab\]) AND (miRNA\* OR microRNA\*) AND (biomarker\*\[tiab\] OR marker\*\[tiab\] OR indicator\*\[tiab\] OR predictor\*\[tiab\])". Here, studies in which miRNAs were exactly defined as markers or biomarkers were mainly considered, and those identified from body fluids such as saliva, urine and sweat were excluded as we only focused on miRNA biomarkers in blood and tissues. Besides, for further comparing the differentiation between HCC and cirrhosis and providing valuable strategies for the early detection of HCC, we also collected diagnostic miRNA biomarkers for liver cirrhosis using retrieval formula "cirrhosis\[tiab\] AND diagnos\*\[tiab\] AND (miRNA\* OR microRNA\*) AND (biomarker\*\[tiab\] OR marker\*\[tiab\] OR indicator\*\[tiab\] OR predictor\*\[tiab\])".

Target genes of miRNA biomarkers
--------------------------------

The miRNA targets used in this study were integrated from both experimentally validated, *i.e.* miR2Disease[@b23], TarBase (version 6.0)[@b24], miRTarBase (version 4.5)[@b25], miRecords (version 4.0)[@b26] and computationally predicted, *i.e.* HOCTAR (version 2.0)[@b27], ExprTargetDB[@b28], and starBase (version 2.0)[@b29] miRNA-target databases. To reduce false positives, we mainly selected miRNA-mRNA pairs validated by low-throughput experiments, *i.e.* real-time quantitative PCR, Western blot, etc. For computationally predicted pairs, they should reside in no fewer than two of the three prediction databases. Meanwhile, we unitized miRNA IDs according to the latest nomenclature in miRBase (release 21)[@b30].

Functional survey of HCC biomarker miRNAs
-----------------------------------------

The functions of HCC biomarker miRNAs are summarized based on the hallmarks of cancers[@b31][@b32]. Since some of the miRNAs are associated with liver injury and few of the miRNAs' functions are unclear, we therefore grouped their functions into 12 categories as antigrowth signals, resisting cell death, avoiding immune destruction, tissue invasion and metastasis, tumor promotion inflammation, sustained angiogenesis, limitless replicative potential, genome instability and mutation, other clinicopathological features, liver injury, tumor suppressor/onco-miR, and unclear. Moreover, we compared the pathogenesis of HCC biomarker miRNAs based on etiological factors as well as ethnic groups, *i.e.* the effects of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and ethnic variation on HCC development.

Pathway enrichment analyses
---------------------------

For better understanding the association between miRNAs and HCC pathogenesis, we mapped the targets of biomarker miRNAs onto signaling pathways using IPA (Ingenuity Pathway Analysis) program. The top 10 significantly enriched pathways (p-value \< 0.01) were selected and further validated the correlation with HCC by PubMed literature exploration.

Results
=======

Overview of the collected HCC biomarker miRNAs
----------------------------------------------

After manually searching and checking in PubMed citations, a total of 50 and 18 diagnostic miRNA biomarkers in blood and tissues, respectively, were extracted from 44 articles (see [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}) and their clinicopathological features of HCC were further compared based on the hallmarks of cancer[@b31], etiological factors and ethnic groups, respectively. As for prognostic and therapeutic biomarkers, respectively, 16 and 32 prognostic miRNAs in blood and tissues together with 8 therapeutic markers were collected according to records in 54 articles (see [Tables 3](#t3){ref-type="table"}, [4](#t4){ref-type="table"} and [5](#t5){ref-type="table"}) and their clinicopathological features as well as functions were then explored.

Functional characterization of HCC biomarker miRNAs based on cancer hallmarks
-----------------------------------------------------------------------------

The functional characterization of HCC biomarker miRNAs are summarized from the primary references and classified into 12 categories as shown in [Fig. 1](#f1){ref-type="fig"}. It indicates that the biomarker miRNAs are associated with all aspects of hallmarks of cancers and all the hallmarks lead to the cancer. Therefore, the personalized biomarkers are needed to precision diagnosis, prognosis and treatment of the complex HCC. The functions of the biomarker miRNAs are summarized as follows.

Insensitivity to Antigrowth Signals
-----------------------------------

Although it is unclear for the units and interconnections between the different kinds of antigrowth and differentiation-including signals and the core cell cycle machinery, an antigrowth signaling must be exist to circumvent developing HCC[@b31]. MiR-125b-5p and miR-15b-5p were the circulating diagnostic miRNA biomarkers associated with insensitivity to antigrowth signals and all of them were up-regulated and highly expressed in early-stage HCC cases[@b33]. Liu *et al*. combined miR-15b-5p and miR-130b-3p as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 in their validation study, the same was found in tissue samples, miR-15-5p was also reported highly expressed[@b34]. As for prognostic biomarkers, three miRNAs related to insensitivity to antigrowth signals in the tissue samples were identified, including miR-137, miR-185-5p and miR-26a-5p. All of them were down-regulated in poor prognostic group which had a lower survival rate and shorter time to recurrence[@b35][@b36][@b37].

Resisting Cell Death
--------------------

Cancer cells evolve various ways to circumvent or restrict apoptosis. The diversity of apoptosis-avoiding machinery and program reflects the multiplicity of apoptosis-including signals that tumor cell populations experienced while their evolution to the malignant state[@b32]. In tissues, miR-101-3p, miR-224-5p and miR-483-5p were associated with resisting cell death. Among them, miR-101-3p was down-regulated whereas the remaining two were reported to be up-regulated[@b38][@b39][@b40]. Resisting cell death was significantly associated with lower expression of miR-101-3p, miR-16-5p, miR-195-5p, miR-203a-3p and miR-221-3p in blood samples[@b38][@b41][@b42][@b43]. Increased miR-221-3p, miR-224-5p, miR-483-5p and miR-122-5p expression were also detected in blood of HCC patients[@b40][@b44]. These above diagnostic biomarkers as classifiers for HCC detection, yielding a receiver operating characteristic curve area of 0.635 to 0.884 (see [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}). On the other hand, miR-155-5p, miR-206, miR-21-5p and miR-212-3p could be recognized as biomarkers for HCC prognosis in tissues. The expression levels of miR-155-5p and miR-21-5p were up-regulated whereas others were down-regulated[@b45][@b46][@b47][@b48]. Circulating miR-122-5p and miR-16-5p could be used as putative biomarkers for HCC. Among them, miR-122-5p and miR-16-5p were shown to be up and down-regulated, respectively[@b49][@b50].

Avoiding Immune Destruction
---------------------------

According to the long-standing theory of immune surveillance proposes, most of solid tumors such as HCC appeared to have somehow controlled to avoid detection by the different kinds of arms of the immune system or could limit the extent of immunological killing, thus they could evade eradication by immune system[@b32]. Motawi and his colleagues overviewed that serum miR-146p-5p was up-regulated in HCC and showed the clinical value for HCV-related HCC diagnosis. This circulatory biomarker miRNA was reported to exerted negative effects on anti-tumor immune response[@b42].

Tissue Invasion and Metastasis
------------------------------

Invasion and metastasis, complex and multi-step processes, are elementary factors that affects HCC patients survival rate and their genetic and biochemical mechanisms remain poorly understood[@b31]. In tissues, high expression of miR-18b-5p, miR-200a-3p, miR-200b-3p, miR-21-5p, miR-224-5p and miR-29-5p were most frequently to be detected in HCC, and miR-139-5p was down-regulated. Therefore, they were valuable for diagnosis of HCC[@b39][@b51][@b52][@b53][@b54][@b55][@b56][@b57]. Several circulating miRNA biomarkers also displayed signally correlation with tissue invasion and metastasis, including highly expressed miR-146a-5p, miR-181b-5p, miR-182-5p, miR-21-5p, miR-215, miR-24-3p, miR-224-5p, miR-296-5p, miR-331-3p and miR-96-5p and low expressed miR-125b-5p, miR-199a-3p, miR-122-5p, miR-139-5p, miR-150-5p, miR-195-5p and miR-19a-3p. The above diagnostic biomarkers could be used as classifiers for HCC detection, yielding a receiver operating characteristic curve area of 0.645 to 0.943[@b42][@b51][@b55][@b56][@b58][@b59][@b60][@b61][@b62][@b63].

In tissues, with regard to up-regulated microRNAs in HCC tissues, highly expression of miR-106b-5p, miR-155-5p, miR-17-5p, miR-182-5p, miR-183-5p, miR-18b-5p, miR-21-5p, miR-25-3p, miR-331-3p, miR-9-5p and miR-96-5p were significantly correlated with invasion and metastasis[@b45][@b47][@b52][@b56][@b64][@b65][@b66][@b67][@b68][@b69][@b70][@b71]. The expression level of miR-1269a in HCC patients without portal vein tumor embolus was reduced[@b72]. In addition, the low expression of miR-125a-5p, miR-128-3p, miR-137, miR-185-5p, miR-188-5p, miR-26a-5p, miR-503-5p and miR-744-5p were detected in HCC tissues compared with their non-tumor livers and were involved in the multi-step processes[@b35][@b36][@b37][@b73][@b74][@b75][@b76]. There were six circulating prognostic biomarker miRNAs reported to be associated with tissue invasion and metastasis, including miR-122-5p, miR-17-5p, miR-182-5p, miR-21-5p, miR-24-3p and miR-331-3p, all of them were up-regulated in the group with low survival rate[@b56][@b61][@b63][@b77][@b78]. Meanwhile, the serum miR-150-5p was shown highly expressed in HCC patients after surgical operation and then low expressed after tumor relapsed[@b60].

Tumor Promoted Inflammation
---------------------------

Inflammation has been proved to be existed at the earliest stage of tumor processes and to be capable of fostering the progression of incipient neoplasia into advanced tumors[@b79]. Besides chemicals, particularly reactive oxygen species were positively mutagenic for adjacent cancer cells, accelerating their genetic evolution towards the high malignant carcinoma[@b80]. In blood, the increased expression of miR-30c-5p could be used as a new classifier for HCV-positive HCC in early-stage[@b81]. In addition, hepatic necroinflammatory activity was associated with the high expression of miR-122-5p in plasma. The over expression of circulating miR-122-5p was a prognostic biomarker predicting the poor survival rate of patients underwent radio frequency ablation[@b49].

Sustained Angiogenesis
----------------------

Both oxygen and nutrients transported by vasculature are essential for cell survival and function. All cells in tissues obligate to live within 100 μm of a capillary blood vessel. The evidence showed that cells with aberrant proliferative lesions tended to lack angiogenic ability at first, and led to hinder the capability for expansion[@b31]. The development of angiogenic ability is vital for incipient neoplasia growth[@b82][@b83]. The over expression of circulating miR-296-5p was significantly associated with tumor angiogenesis[@b42]. In tissues, high expression of miR-26a-5p could suppress tumor angiogenesis in HCC by targeting HGF-cMet signaling, and it was a novel prognostic biomarker for HCC[@b84].

Limitless Replicative Potential
-------------------------------

There are three factors can lead to an uncoupling of the growth of a cell process from signals in their microenvironment, including insensitivity to antigrowth signals, resistance to apoptosis, and growth signal autonomy. Senescence, just like apoptosis, is as a protective system that could be activated by opposite growth signals or shortened telomeres that drives abnormal cells irreversibly into a G0-like state, and it could prevent further proliferation[@b31]. High expression of miR-182-5p, miR-18b-5p, miR-21-5p and miR-224-5p, together with the down-regulated expression of miR-101-3p and miR-139-5p not only played important roles in the regulation of cell proliferation and limitless replicative potential, but also were diagnostic signals for HCC[@b38][@b39][@b51][@b52][@b54][@b55][@b56][@b85]. High expression of miR-106b-5p, miR-21-5p, miR-331-3p and low expression of miR-101-3p, miR-125b-5p, miR-139-5p had great potential to be noninvasive and accurate circulating biomarkers for HCC preliminary screening[@b10][@b38][@b51][@b55][@b56][@b61]. Moreover, some opposite results about the expression levels of miR-122-5p were discussed[@b44][@b86]. In tissues, high expression of eight miRNAs (*i.e.* miR-101-3p, miR-106-5p, miR-17-5p, miR-18b-5p, miR-21-5p, miR-25-3p and miR-331-3p) and low expression of seven miRNAs (*i.e.* miR-125a-5p, miR-128-3p, miR-188-5p, miR-206, miR-212-3p, miR-424-5p and miR-744-5p) were outstandingly correlated with limitless replicative potential and could provide positive prognostic values for HCC[@b38][@b46][@b47][@b48][@b52][@b56][@b64][@b65][@b69][@b70][@b73][@b74][@b76][@b87]. Four prognostic circulating miRNAs associated with proliferation and limitless replicative potential, including miR-101-3p, miR-122-5p, miR-21-5p and miR-331-3p, were reported up-regulated in HCC patients[@b38][@b56][@b61][@b77].

Genome Instability and Mutation
-------------------------------

Multi-step cancer progression could be described as a series of genic clonal expansions. Acquiring the chance of an enabling mutant gene triggered these clonal expansions[@b88][@b89][@b90]. The widespread destabilization of genome is inherent to the vast majority of HCC cells[@b32]. The high expression of miR-122-5p and low expression of miR-143-3p in blood were prominently correlated with differentiation and genome instability. They could be used as noninvasive circulating biomarkers for diagnosis of HCC[@b59][@b62][@b86]. Up-regulated expression of miR-21-5p has been observed to be associated with genome instability and mutation, and it was a novel prognostic biomarker for HCC[@b68]. Patients with high serum concentrations of miR-1-3p and miR-122-5p showed a long overall survival time and these miRNAs could be used to assess the HCC staging scores[@b77][@b91].

Liver injury
------------

Biochemical molecules including miRNAs can be released into the circulation system due to the hypoxia and damage of liver cells. Accumulating reports indicated that serum miR-10b-5p, miR-122-5p, miR-18-5p, miR-192-5p, miR-21-5p, miR-223-3p and miR-885-5p were went up in patients with chronic hepatitis or HCC and they could serve as diagnostic biomarkers for liver injury but not specific for HCC[@b10][@b42][@b92][@b93][@b94].

Tumor suppressor/onco-miR
-------------------------

Genetic suppressor and carcinogenicity interpreted the function of miRNAs from another perspective. In tissues, high expression of miR-150-5p and miR-29a-5p and low expression of miR-101-3p, miR-126-3p, miR-127-3p, miR-139-5p and miR-214-3p played tumor-suppressor roles and could be used as diagnostic biomarkers for HCC[@b38][@b39][@b51][@b57][@b95][@b96][@b97]. The circulating miR-101-3p, miR-122-5p, miR-125b-5p, miR-139-5p, miR-150-5p, miR-16-5p, miR-181a-5p, miR-199a-3p, miR-199a-5p, miR-203a-3p, miR-21-5p, miR-22-3p, miR-29b-3p, miR-375, let-7b-5p correlated with tumor suppressor and could be potential biomarkers to differentiate HCC from healthy controls[@b10][@b38][@b41][@b44][@b51][@b58][@b59][@b60][@b86][@b97][@b98]. On the other hand, miR-101-3p, miR-122-5p, miR-125b-5p, miR-130a-3p, miR-146a-5p, miR-214-3p and miR-99a-5p were considered as tumor suppressors in HCC and served as prognostic indicators for HCC[@b38][@b99][@b100][@b101][@b102][@b103][@b104]. Serum miR-1-3p, miR-101-3p, miR-122-5p, miR-150-5p, miR-203a-3p and miR-30c-5p were associated with suppressing tumorigenicity and new independent parameters of overall survival in HCC[@b38][@b49][@b60][@b77][@b91][@b105].

The high expression of miR-130b-3p, miR-148a-3p, miR-181b-5p, miR-221-3p, miR-885-5p and miR-96-5p were functional in tumorigenicity and could be served as early diagnostic biomarkers for different tumor type[@b34][@b106]. Meanwhile, miR-10b-5p, miR-130b-3p, miR-146a-5p, miR-18-5p, miR-195-5p, miR-196a-5p and miR-27a-3p were related to carcinogenicity and played vital roles in HCC detection[@b10][@b34][@b42][@b59][@b94][@b107]. There were six miRNAs associated with oncogenicity and could be potential biomarkers for the overall survival of patients with HCC, including miR-1269a, miR-155-5p, miR-182-5p, miR-183-5p, miR-96-5p and miR-128-2[@b66][@b72][@b108][@b109].

Other clinicopathological features
----------------------------------

Besides the above ten clinicopathological features and the hallmarks of cancer, biomarker miRNAs were also correlated with other clinicopathological features, such as secretion by primary cancer cells, child stage, cholesterol reverse transport, tumor size and recurrence, etc. Tomimaru *et al*. found that miR-21-5p was excessively secreted by primary cancer cells and could be a potential diagnostic biomarker for HCC[@b110]. Motawi and his colleagues identified that serum miR-34a-5p was correlated with child stage and BCLC score and could be used as an early biomarkers for HCC in high-risk group[@b42]. The miR-885-5p and miR-122-5p in serum was reported related to cholesterol reverse transport and assessment of liver pathologies[@b111]. In addition, miR-101-3p, miR-106b-5p, miR-130a-3p, miR-16-5p, miR-199a-5p, let-7f-5p and miR-34a-5p were found to have a significant correlation with tumor size in the tissue and serum of HCC patients[@b50][@b64][@b102][@b112][@b113][@b114]. The present literature also provided evidence that miR-130a-3p, miR-21-5p, miR-25-3p, miR-17-5p were independent prognostic factors and were associated with the TNM classification which is a universally accepted cancer staging system based on extension and size of the primary tumor (T), the adjacent lymph node (N), and the distant metastasis (M)[@b68][@b69][@b78][@b102]. The down-regulated expression of miR-774-5p and let-7f-5p can be considered as noninvasive biomarkers for predicting of the recurrence of HCC[@b76][@b114].

Comparison of HCC biomarker miRNAs based on etiological factors and ethnic groups
---------------------------------------------------------------------------------

Recently, accumulating evidence indicated that the occurrence and development of HCC are closely associated with etiological factors as well as ethnic groups. The differentiation between HCC and liver cirrhosis, for instance, is one of the main problems for the early detection of HCC. Moreover, different etiological factors such as HBV (Hepatitis B Virus) and HCV (Hepatitis C Virus) can also contribute to the HCC carcinogenesis. On the other hand, the incidence and mortality of HCC often showed different patterns among different ethnic groups. Hence it is necessary to compare HCC biomarker miRNAs based on etiological factors and ethnic groups.

Biomarker miRNAs for classifying of HCC and liver cirrhosis
-----------------------------------------------------------

After manually searching for citations in PubMed, a total of 13 miRNA biomarkers for liver cirrhosis diagnosis were collected (see [Table S1](#S1){ref-type="supplementary-material"}). We then compared them with HCC diagnostic miRNA biomarkers in order to screen key signatures for HCC early detection. As shown in [Fig. 2](#f2){ref-type="fig"}, eight miRNAs, *i.e.* miR-106b-5p, miR-122-5p, miR-141-3p, miR-146a-5p, miR-181b-5p, miR-18a-5p, miR-19a-3p and miR-21-5p, were shared by cirrhosis and HCC. Interestingly, three of them (miR-106b-5p, miR-18a-5p and miR-21-5p) showed inverse expression patterns in cirrhosis and HCC groups. For example, the expression of miR-106b-5p (miR-106b) was down in cirrhosis samples[@b115] whereas it turned out to be up-regulated in the blood of HCC patients[@b10]. In addition, miR-19a-3p (miR-19a) was reported as a useful molecular marker for monitoring the progression of liver fibrosis to cirrhosis and finally, to HCC[@b42].

The remaining 5 and 49 miRNAs, respectively, were specific to cirrhosis and HCC, which could be served as independent factors for classifying of cirrhosis and HCC. For example, miR-29c-3p showed significant positive correlations with the level of serum cholinesterase (CHE) and albumin (ALB) in liver cirrhosis patients, suggesting that the miRNA played functional roles in the establishment of liver cirrhosis[@b116]. Han *et al*. found that two miRNAs, *i.e.* miR-224 (miR-224-5p) and miR-214 (miR-214-3p), were significantly up- and down-regulated in HCC tissue samples respectively, which provided novel biomarker signatures for HCC diagnosis and treatment[@b39].

It can be concluded that biomarker miRNAs revealed the pathogenesis of cirrhosis and HCC at the post-transcriptional level and could help deeply understand the differentiation between cirrhosis and HCC. From the perspective of precision medicine, HCC miRNA biomarkers, especially those specific to HCC, were indicators for capturing the early diagnostic signatures at the time of HCC initiation.

Biomarker miRNAs for monitoring the development of HBV/HCV-related HCC
----------------------------------------------------------------------

It has been widely acknowledged that the progression of HCC is closely affected by the infection of etiological factors, such as HBV, HCV, etc. On the other hand, miRNAs are reported to play crucial roles in HBV/HCV replication and pathogenesis[@b117][@b118][@b119], *i.e.* they regulated HBV by directly binding to HBV transcripts or changing HBV gene expression at the transcriptional level[@b118]. For better investigating the influence of HBV/HCV on HCC development, miRNA biomarkers for HBV/HCV-related HCC were extracted from our collected dataset. As illustrated in [Fig. 3](#f3){ref-type="fig"}, several miRNAs, *i.e.* miR-122-5p, miR-126-3p, miR-143-3p, miR-192-5p, etc., were functional in both HBV- and HCV-related HCC evolutionary progression. For example, Tan *et al*. found that serum miR-122-5p could be used as the diagnostic biomarker for detecting HBV-related HCC. Both the area under the receiver operating characteristic curve (AUC) and logistic regression model convinced the predictive power[@b86]. Meanwhile, the miRNA was also turned out to be effective for early detection of HCC on top HCV infection. Using the miRNA panel where miR-122-5p included, HCC patients could be classified from healthy controls and liver cirrhosis patients with high diagnostic accuracy[@b120].

There is still a large number of biomarker miRNAs that could be specifically used for monitoring the development of HBV/HCV-related HCC. Chen *et al*. analyzed the plasma samples from 242 individuals and uncovered that the expression of miR-125b-5p (miR-125b) was significantly down-regulated in HBV-induced HCC (HBV-HCC) patients compared to healthy controls as well as HBV groups without HCC[@b121]. Moreover, the low plasma level of miR-125b-5p also reflected the higher possibility of metastasis. Therefore, the miRNA held promise as a valuable diagnostic biomarker for HBV-HCC and HBV-infected patients with high HCC risks could be early detected by dynamically monitoring the changes of this miRNA. Liu *et al*. demonstrated that the expression levels of miR-30c-5p (miR-30c) and miR-203a-3p (miR-203a) were crucial indicators for predicting the poor prognosis of HCV-related HCC because the core protein of HCV could down-regulate the expression of miR-30c-5p and miR-203a-3p, resulting in the activation of epithelial-mesenchymal transition in normal hepatocytes as well as HCC tumor cells. As reported before, the activation process may contribute to the carcinogenesis of HCC[@b105].

Understanding the pathogenesis of miRNA biomarkers in HBV/HCV-related HCC provided insights to evaluate the potential effects of HBV/HCV on HCC development, which will be helpful to the early and personalized detection of HCC.

HCC miRNA biomarkers within different ethnic groups
---------------------------------------------------

Genomic profiling of HCC tumors showed that HCC patients in different geographic regions tended to have specific recurrent molecular aberrations[@b122]. Asians, on the whole, achieved the highest HCC incidence according to the report by Wong *et al*.[@b123]. In terms of prognosis, the overall survival rate was also disparate among different ethnic groups[@b124]. Here we reorganized HCC miRNA biomarkers based on the ethnicity of patients described in each citation. As illustrated in [Fig. 4a](#f4){ref-type="fig"}, most of the reported HCC miRNA biomarkers were related to Chinese population, which indirectly indicated the high risk or high incidence of HCC in China. For further exploring the ethnic specificity of HCC miRNA biomarkers, we then partitioned miRNAs into two categories based on the patient race, *i.e.* Asian-related (Chinese, Japanese, South Korean, Indian and Iranian) and non-Asian-related (Egyptian, American, Turk and German) HCC miRNA biomarkers. As shown in [Fig. 4b](#f4){ref-type="fig"}, the number of Asian-specific HCC miRNA biomarkers is far more than that of non-Asian. We noticed that some miRNAs were reported to be functional in both Asian and non-Asian group. However, the expression pattern of them was sometimes quite different when they were involved in different pathogenic processes or belonged to different ethnic groups. For example, miR-125b-5p was associated with the biological behavior of HCC and had the diagnostic value of HCC for both Turks and Chinese. As in plasma samples of Chinese patients, it was found to be down-regulated[@b121] whereas in Turks samples, its expression level was up[@b33]. For comparison of Egyptian and Chinese, the down-regulation of miR-146a-5p was correlated with HCC carcinogenesis and deterioration in Chinese population[@b103], but in samples of Egyptian patients, it was inverse[@b42].

This ethnic difference may be caused by the heterogeneous pathogenesis, lifestyles and various factors including the diet, environmental exposures, *etc.* Moreover, the incidence of HBV/HCV infection in different countries is also inconsistent. Therefore, more in-depth researches on ethnically specific miRNA biomarkers is of clinical significance, which would provide personalized strategies for HCC diagnosis and treatment in the era of precision medicine.

Pathway enrichment analysis for targets of HCC miRNA biomarkers
---------------------------------------------------------------

We performed the pathway enrichment analysis for targets of different types of reported miRNA biomarkers using IPA program. Here the targets of miRNA biomarkers originated from seven publicly available miRNA-target databases, including four experimentally validated databases and three computationally predicted databases (see Methods). For the three categories, *i.e.* the diagnostic, prognostic and therapeutic biomarker miRNAs, the top 10 significantly enriched pathways (p-value \< 0.01) were chosen and shown in [Fig. 5](#f5){ref-type="fig"}. The common enriched pathways among them were Molecular Mechanisms of Cancer, Glucocorticoid Receptor Signaling, HGF Signaling, NGF Signaling, p53 Signaling etc. Most of them are well-studied cancer associated pathways. Das *et al*. reported that the pathway Molecular Mechanisms of Cancer was potentially associated with recurrent HCC secondary to HCV following liver transplantation[@b125]. Glucocorticoids are involved in controlling many essential biological processes that are related to energy supply and growth control. The Glucocorticoid Receptor often functions as a cofactor of transcription factor STAT5 for growth hormone induced genes and Glucocorticoid Receptor Signaling has been turned out to be important in body growth, steatosis and metabolic liver cancer development[@b126]. The experimental result in mouse model demonstrated that the metabolic dysfunction and impairment of Glucocorticoid Receptor Signaling could cause steatosis and HCC in mice[@b127]. Wu *et al*. revealed that the HGF signaling could be activated by over expression of gene C1GALT1 in HCC via modulation of MET O-glycosylation and dimerization, which offered new insights into O-glycosylation and HCC pathogenesis[@b128]. Jin *et al*. indicated that p53 Signaling pathway was significantly dysregulated in HCC and it could reflect the development and progression of HCC[@b129]. Moreover, a number of genes participated in regulating human HCC by interacting with p53 Signaling pathway. For instance, the key gene RASSF10, which is located on chromosome 11p15.2, could suppress the growth of HCC via activating p53 Signaling pathway[@b130]. EGR1 is one of the key components in p53 Signaling, the re-expression of gene BCL6B in HCC cells could increase its expression and finally contribute to the activation of p53 Signaling[@b131].

Discussion
==========

In this review, we made comprehensive functional survey and comparison of HCC diagnostic, prognostic and therapeutic miRNAs in blood and tissues. The number of diagnostic miRNA biomarkers in blood is approximately twice as much as those in tissues and meanwhile, the number of prognostic miRNA biomarkers in tissues is twice as much as those in blood. The reason for the statistical difference may be that many studies are inclined to investigate the noninvasive diagnostic miRNA biomarkers and researchers tend to use relatively stable hepatogenic biomarkers as prognostic indicators because miRNAs may be released into the blood selectively[@b132][@b133]. Most of the diagnostic, prognostic and therapeutic miRNA biomarkers are associated with one or two clinic pathological features in blood and tissues. A great number of prognostic biomarkers with high expression levels were detected in patients with shorter overall survival. Since the etiological factors as well as ethnic groups are closely associated with HCC carcinogenesis, we analyzed miRNA biomarkers by taking the HBV/HCV infection as well as regional variations into account in order to provide better clues for HCC pathogenic research. We mainly selected miRNAs which were explicitly reported as HCC markers/biomarkers in our current study. Besides, several miRNAs are still common and important during HCC development. For example, miR-142-3p was functional in HCC tumorigenesis and played a key role in regulating human RAC1 gene. The upregulation of miR-142-3p inhibited the expression level of RAC1 mRNA, suppressing the migration and invasion of HCC cells[@b134]. Interferon regulatory factor-1 (IRF-1) is a tumor-suppressor in HCC and its down-expression would help HCC tumors evade death. Yan *et al*. found that miR-23a was a negative regulator of IRF-1in HCC, which highlighted its importance in HCC initiation and progression[@b135]. Zhang *et al*. demonstrated that miR-99a could directly regulate AGO2 and control tumor growth in HCC, indicating the potential strategies for HCC treatment[@b136].

HCC is a complex disease which is difficult for early diagnosis and treatment. The death rate of HCC remains high due to its poor prognosis. To some extent, miRNAs are effective biomarkers for HCC because of the noninvasive detection, good specificity and sensitivity. More systematic investigations and clinical experiments need to be done for better understanding the role and function of miRNA biomarkers in HCC pathogenesis[@b137][@b138][@b139].
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![The correlation among clinicopathological features and reported HCC miRNA biomarkers.\
Here, miRNAs in red and green, respectively, represent the up and down-regulated expression in tissues and blood. The miRNA in black means that its expression can be inconsistently up- or down- regulated in different reports. Sub-figure (**a**,**b**) represent clinicopathological features of diagnostic miRNA biomarkers in tissues and blood, respectively. Sub-figure (**c**,**d**) represent clinicopathological features of prognostic miRNA biomarkers in tissues and blood, respectively.](srep38311-f1){#f1}

![The Venn diagram of miRNA biomarkers for liver cirrhosis and HCC.\
Here circles in blue and red, respectively, represent miRNAs for cirrhosis and HCC. The miRNAs in red and green represent the up- and down-regulated expression, respectively. The miRNAs in purple means they showed inverse expression patterns in cirrhosis and HCC samples and those in black means their expressions were inconsistently up- or down- regulated according to different literature reports.](srep38311-f2){#f2}

![The Venn diagram of miRNA biomarkers for HBV/HCV-related HCC.\
Here miRNA biomarkers for HBV/HCV-related HCC were extracted from our collected dataset. Circles in blue and red, respectively, represent miRNAs for HBV-related HCC and HCV-related HCC. The miRNAs in orange and dark green represent the diagnostic and prognostic markers, respectively. The miRNAs in brown means they had both diagnostic and prognostic role according to different literature reports.](srep38311-f3){#f3}

![HCC miRNA biomarkers in different ethnic groups.\
Here miRNA biomarkers were classified based on the race/nation of patients described in each citation. Sub-figure (**a**) represents the distribution of reported HCC miRNA biomarkers in different national cohorts. Bars in blue, red and green mean the number of total, diagnostic and prognostic miRNA biomarkers, respectively. Sub-figure (**b**) is the Venn diagram of HCC miRNA biomarkers for Asian and non-Asian respectively. Circles in blue and red, respectively, represent Asian-related and non-Asian-related miRNA biomarkers. The miRNAs in orange and dark green represent the diagnostic and prognostic markers, respectively. The miRNAs in brown means they had both diagnostic and prognostic role according to different literature reports.](srep38311-f4){#f4}

![Top 10 pathways significantly enriched with targets of different biomarker miRNAs from HCC tissue and blood.\
Sub-figure (**a**), (**b**), and (**c**) represent pathways enriched by targets of diagnostic, prognostic and therapeutic biomarker miRNAs, respectively. The statistical significance level (p-value) was negative 10-based log transformed.](srep38311-f5){#f5}

###### Diagnostic biomarkers in tissues for hepatocellular carcinoma.

  Reported ID    Offical ID                 Sample                 Ethnicity  Features                                                                   Expression                               AUC                                     PMID                    Validated Targets
  ------------- ------------- ----------------------------------- ----------- ------------------------------------------------------------------------- ------------ -------------------------------------------------------------- ----------------- -----------------------------------------
  miR-101        miR-101-3p    30 HC 67 CHB 61 HBV-LC 67 HBV-HCC     China    1.inhibit HCC cell proliferation2.tumor suppressor3.promote apoptosis         down      CHB from HC 0.635 HBV-LC from HC 0.884 HBV-HCC from HC 0.788   24971953[@b38]                  Mcl-1, SOX9
  miR-126        miR-126-3p              19 HCV 6 HCC               Germany   tumor suppressor                                                              down                                   NA                                25500075[@b95]                      NA
  miR-127        miR-127-3p                 33 HCC                   China    tumor suppressor                                                              down                                   NA                                24854842[@b96]                      NA
  miR-130b       miR-130b-3p                97 HCC                   China    onco-miR                                                                       up                                  0.914                               22403344[@b34]                     RUNX3
  miR-139        miR-139-5p              31 CHB 31 HCC               China    1.suppress metastasis and progression of cancer cells2.tumor suppressor       down                     HCC from CH 0.761 (0.770[@b1])                  24549282[@b51]                 Rho-kinase 2
  miR-148a       miR-148a-3p                19 HCC                   China    onco-miR                                                                       up                                    NA                                22496917[@b106]                     NA
  miR-150        miR-150-5p              15 HC 15 ICC                China    tumor suppressor                                                               up                                  0.764                               25482320[@b97]                      NA
  miR-15b        miR-15b-5p                 96 HCC                   China    preventing replicative stress in response to mitogenicsignalling               up                                0.98[@b2]                             22403344[@b34]                      NA
  miR-182        miR-182-5p                   HCC                    China    proliferation                                                                  up                                    NA                                24653623[@b85]                IGF1R and GSK3B
  miR-18b        miR-18b-5p                 110 HCC                  Japan    1.proliferation2.loss of cell adhesion ability                                 up                                    NA                                23496901[@b52]                    TNRC6B
  miR-199a       miR-199a-5p             17 CH 23 HCC                Egypt    NA                                                                            down                                 0.856                               26302751[@b54]    Mitogen-activated protein kinase (MAPK)
  miR-200a       miR-200a-3p                29 HCC                  Germany   suppress cancer cell migration                                                 up                                    NA                                24895326[@b53]                   ZEB1/ZEB2
  miR-200b       miR-200b-3p                29 HCC                  Germany   suppress cancer cell migration                                                 up                                    NA                                24895326[@b53]                   ZEB1/ZEB2
  miR-21          miR-21-5p           50 HC 30 LC 136 HCC            Japan    excessive secretion by primary cancer cells                                    up                    CH from HC 0.773 HCC from HC 0.953                21749846[@b110]                     NA
  miR-21          miR-21-5p              17 CH 23 HCC                Egypt    1.cell growth2.migration3.invasion                                             up                                  0.943                               26302751[@b54]     phosphatase and tensin homolog (PTEN)
  miR-21          miR-21-5p              30 HC 97 HCC                China    1.promote cell proliferation2.tumor invasion                                   up                                    NA                                25973032[@b55]                PDCD4 and PTEN
  miR-21          miR-21-5p                 74 ICC                   China    intrahepatic cholangiocarcinoma proliferation and growth                       up                                    NA                                25803229[@b56]                PTPN14 and PTEN
  miR-214        miR-214-3p               9 HC 10 HCC                China    tumor suppressor                                                              down                                   NA                                24789420[@b39]             EZH2, CTNNB1 and CDH1
  miR-224        miR-224-5p               9 HC 10 HCC                China    1.cell proliferation2.migration3.invasion4.anti-apoptosis                      up                                    NA                                24789420[@b39]                     CD40
  miR-29a-5p     miR-29a-5p                 266 HCC                  China    1.tissue invasiveness and metastasis r2.tumor suppresso                        up                                  0.746                               23285022[@b57]                      NA
  miR-483-5p     miR-483-5p              69 HC 69 HCC               America   anti-apoptotic oncogene                                                        up                            HCC from HC 0.827                         24127413[@b40]                      NA

Abbreviations and note: HC: healthy controls; CHB: patients with chronic type B hepatitis; CH: chronic hepatitis; HCV: hepatitis C virus; HCC: hepatocellular carcinoma; LC: liver cirrhosis; HBV: hepatitis B virus; ICC: Intrahepatic cholangiocarcinoma; NA: not available; 1: combination of plasma miRNA-139 with serum AFP; 2: combined miR-15b and miR-130b.

###### Diagnostic biomarkers in blood for hepatocellular carcinoma.

  Reported ID    Offical ID                                Sample                               Source   Ethnicity  Features                                                                                         Expression                               AUC                                     PMID                Validated Targets
  ------------- ------------- ---------------------------------------------------------------- -------- ----------- ----------------------------------------------------------------------------------------------- ------------ -------------------------------------------------------------- ----------------- ----------------------------------
  miR-199a-3p    miR-199a-3p                           156 HC 78 HCC                            serum      China    invasion capability                                                                                 down                                 0.883                               25618599[@b58]       phosphorylated-S6 protein
  miR-223        miR-223-3p                    167 HC 169 CHB 141 LC 457 HCC                    blood      China    NA                                                                                                  down               0.864(training set) 0.888(validation set)             22105822[@b59]               Stathmin1
  miR-101        miR-101-3p                  30 HC 79 CHB 61 HBV-LC 67 HBV-HCC                  serum      China    1.inhibit HCC cell proliferation2.tumor suppressor3.promote apoptosis                            down[@b1]    CHB from HC 0.635 HBV-LC from HC 0.884 HBV-HCC from HC 0.788   24971953[@b38]              Mcl-1, SOX9
  miR-106b       miR-106b-5p                        50 HC 31 CLD 27 HCC                         blood      China    Proliferation                                                                                        up           HCC from HC 0.89 HCC from CLD 0.81 CLD from HC 0.63        25761179[@b10]                p21/E2F5
  miR-10b        miR-10b-5p                         50 HC 31 CLD 27 HCC                         blood      China    1.onco-miR2.liver injury                                                                             up           HCC from HC 0.85 HCC from CLD 0.73 CLD from HC 0.66        25761179[@b10]                   NA
  miR-122        miR-122-5p                         89 HC 48 CHB 101 HCC                        blood      China    liver injury                                                                                         up                    HCC from HC 0.79 CHB from HC 0.93                 21229610[@b92]                   NA
  miR-122        miR-122-5p                    167 HC 169 CHB 141 LC 457 HCC                    blood      China    1.tumor size2.differentiation grade3.poor prognosis4.distance metastasis                            down               0.864(training set) 0.888(validation set)             22105822[@b59]                   NA
  miR-122        miR-122-5p                         15 HC 30 DN 120 HCC                         serum      China    1.induce apoptosis2.suppress proliferation                                                           up                                  0.629                               26264553[@b44]                   NA
  miR-122        miR-122-5p                       34 HC 70 HBV-HCC 48 CHB                       serum      China    liver injury                                                                                         up                 HCC from HC 0.869 HBV-HCC from CHB 0.630             22174818[@b93]                   NA
  miR-122-5p     miR-122-5p                        173 HC 233 LC 261 HCC                        serum      China    1.regulating hepatocyte development and differentiation2.apoptosis and suppress proliferation       down              0.887(training sets) 0.879(validation sets)            25238238[@b86]         HepG2 and Hep3B cells
  miR-1228-5p    miR-1228-5p                       173 HC 233 LC 261 HCC                        serum      China    NA                                                                                                   up               0.887(training sets) 0.879(validation sets)            25238238[@b86]                   NA
  miR-122a       miR-122-5p                        85 volunteers matched                        serum      China    tumor suppressor                                                                                    down                           0.707(0.943)[@b2]                         23723713[@b98]                   NA
  miR-125b-5p    miR-125b-5p                 28 HC 24 CHB 22 HBV-LC 20 HBV-HCC                  plasma    Turkey    suppress the cell growth                                                                             up                                    NA                                24595450[@b33]                  AKT
  miR-130a       miR-130a-3p                   42 HC 125 HCV-CLD 112 HCV-HCC                    blood      Egypt    NA                                                                                                   up                           HCV-HCC from HC 0.91                       26352740[@b42]                   NA
  miR-130b       miR-130b-3p                               97 HCC                               serum      China    onco-miR                                                                                             up                                  0.914                               22403344[@b134]                RUNX3
  miR-139        miR-139-5p                            31 CHB 31 HCC                            plasma     China    1.suppress metastasis and progression of cancer cells2.tumor suppressor                             down                     HCC from CH 0.761 (0.770)[@b3]                  24549282[@b51]              Rho-kinase 2
  miR-141-3p     miR-141-3p                        173 HC 233 LC 261 HCC                        serum      China    NA                                                                                                   up               0.887(training sets) 0.879(validation sets)            25238238[@b86]                   NA
  miR-143        miR-143-3p                         127 HC 118 CH 95 HCC                        serum      China    differentiation                                                                                      up                    CH from HC 0.617 HCC from CH 0.795                24993656[@b62]                 FNDC3B
  miR-146a       miR-146a-5p                   42 HC 125 HCV-CLD 112 HCV-HCC                    blood      Egypt    1.suppresses HCC invasion2.exerted negative effects on anti-tumor immune response                    up             HCV-HCC from HC 0.787 HCV-HCC from HCV-CLD 0.85          26352740[@b142]                 VEGF
  miR-146a       miR-146a-5p                           313 HC 294 HCC                           serum      China    onco-miR                                                                                             NA                                    NA                                24816919[@b107]                  NA
  miR-150        miR-150-5p                        120 HC 110 CHB 120 HCC                       serum      China    1.tumor suppressor2.metastasis3.BCLC stage4.advanced TNM stages                                     down                                 0.931                               26215970[@b60]                   NA
  miR-150        miR-150-5p                             15 HC 15 ICC                            plasma     China    tumor suppressor                                                                                     up                                  0.764                               25482320[@b97]                   NA
  miR-15b        miR-15b-5p                                96 HCC                               serum      China    preventing replicative stress in response to mitogenicsignalling                                     up                                0.98[@b4]                             22403344[@b34]                   NA
  miR-16          miR-16-5p                           107 CLD 105 HCC                           serum     America   1.tumor suppressor2.apoptosis                                                                       down                                   NA                                21278583[@b41]        BCL2, MCL1, CCND1, WNT3A
  miR-17-5p       miR-17-5p             28 HC 26 CHC 30 HCV-positive cirrhosis 8 HCC            blood     Turkey    NA                                                                                                   up                                    NA                                25391771[@b81]                   NA
  miR-181a       miR-181a-5p                        50 HC 31 CLD 27 HCC                         blood      China    tumor suppressor                                                                                    down          HCC from HC 0.82 HCC from CLD 0.71 CLD from HC 0.64        25761179[@b10]                   NA
  miR-182        miR-182-5p                         40 HC 95 BLD 103 HCC                        serum      China    1.metastasis                                                                                         up                                  0.911                               25903466[@b61]                TP53INP1
  miR-18a        miR-18a-5p                     60 HC 30 HBV-CH 101 HBV-HCC                     serum      China    1.liver injury2.onco-miR                                                                             up                                    NA                                22865399[@b94]                   NA
  miR-192        miR-192-5p                    167 HC 169 CHB 141 LC 457 HCC                    blood      China    NA                                                                                                   up                0.864(training set) 0.888(validation set)             22105822[@b59]                   NA
  miR-192        miR-192-5p                    42 HC 125 HCV-CLD 112 HCV-HCC                    blood      Egypt    liver injury                                                                                         up             HCV-HCC from HC 0.878 HCV-HCC from HCV-CLD 0.69          26352740[@b42]                   NA
  miR-192-5p     miR-192-5p                        173 HC 233 LC 261 HCC                        serum      China    NA                                                                                                  down              0.887(training sets) 0.879(validation sets)            25238238[@b86]                   NA
  miR-195        miR-195-5p                    42 HC 125 HCV-CLD 112 HCV-HCC                    blood      Egypt    1.onco-miR2.evading apoptosis3.tissue invasion and metastasis                                       down            HCV-HCC from HC 0.653 HCV-HCC from HCV-CLD 0.78          26352740[@b42]              FGF7 and GHR
  miR-196a       miR-196a-5p                           313 HC 294 HCC                           serum      China    onco-miR                                                                                             NA                                    NA                                24816919[@b107]                  NA
  miR-199a-5p    miR-199a-5p                       173 HC 233 LC 261 HCC                        serum      China    tumor suppressor                                                                                    down              0.887(training sets) 0.879(validation sets)            25238238[@b86]                   NA
  miR-19a        miR-19a-3p                    42 HC 125 HCV-CLD 112 HCV-HCC                    blood      Egypt    1.PV thrombosis2.invasion, satellite nodules and progression3.recurrence                            down            HCV-HCC from HC 0.714 HCV-HCC from HCV-CLD 0.86          26352740[@b42]                   NA
  miR-206          miR-206                         173 HC 233 LC 261 HCC                        serum      China    NA                                                                                                   up               0.887(training sets) 0.879(validation sets)            25238238[@b86]                   NA
  miR-21          miR-21-5p                         89 HC 48 CHB 101 HCC                        blood      China    liver injury                                                                                         up                    HCC from HC 0.87 CHB from HC 0.91                 21229610[@b92]                   NA
  miR-21          miR-21-5p                    167 HC 169 CHB 141 LC 457 HCC                    blood      China    tumor suppressor                                                                                     up                0.864(training set) 0.888(validation set)             22105822[@b59]                  PTEN
  miR-21          miR-21-5p                         50 HC 30 LC 136 HCC                         serum      Japan    excessive secretion by primary cancer cells                                                          up                    CH from HC 0.773 HCC from HC 0.953                21749846[@b110]                  NA
  miR-21          miR-21-5p                             30 HC 97 HCC                            blood      China    1.promote cell proliferation2.tumor invasion                                                         up                                    NA                                25973032[@b55]             PDCD4 and PTEN
  miR-21          miR-21-5p                                74 ICC                               serum      China    intrahepatic cholangiocarcinoma proliferation and growth                                             up                                    NA                                25803229[@b56]            PTPN14 and PTEN
  miR-215          miR-215                          127 HC 118 CH 95 HCC                        serum      China    metastasis                                                                                           up                    CH from HC 0.802 HCC from HC 0.816                24993656[@b62]                   NA
  miR-221        miR-221-3p                  10 HC 30 HCV 30 HCV-LC 30 HCV-HCC                  serum      Egypt    anti-apoptotic                                                                                      down                                 0.655                               25429320[@b43]                   NA
  miR-223        miR-223-3p                         89 HC 48 CHB 101 HCC                        blood      China    liver injury                                                                                         up                    HCC from HC 0.86 CHB from HC 0.88                 21229610[@b92]                   NA
  miR-223-3p     miR-223-3p                     28 HC 26 CHC 30 HCV-LC 8 HCC                    blood     Turkey    NA                                                                                                  down                                   NA                                25391771[@b81]                   NA
  miR-223-3p     miR-223-3p                  28 HC 24 CHB 22 HBV-LC 20 HBV-HCC                  plasma    Turkey    NA                                                                                                  down                                   NA                                24595450[@b33]                   NA
  miR-24-3p       miR-24-3p                         46 HC 31 CLD 84 HCC                         serum      China    1.vascular invasion                                                                                  up                     HCC from CLD 0.636 (0.834)[@b5]                  25129312[@b63]                   NA
  miR-26a        miR-26a-5p                    167 HC 169 CHB 141 LC 457 HCC                    blood      China    lower miR-26a expression experienced worse survival but better response to interferon therapy       down               0.864(training set) 0.888(validation set)             22105822[@b59]                   NA
  miR-26a-5p     miR-26a-5p                        173 HC 233 LC 261 HCC                        serum      China    NA                                                                                                  down              0.887(training sets) 0.879(validation sets)            25238238[@b86]                   NA
  miR-27a        miR-27a-3p                    167 HC 169 CHB 141 LC 457 HCC                    blood      China    onco-miR                                                                                            down               0.864(training set) 0.888(validation set)             22105822[@b59]                   NA
  miR-296        miR-296-5p                    42 HC 125 HCV-CLD 112 HCV-HCC                    blood      Egypt    1.metastasis2.tumor angiogenesis                                                                     up             HCV-HCC from HC 0.792 HCV-HCC from HCV-CLD 0.645         26352740[@b42]                   NA
  miR-302c-3p    miR-302c-3p            28 HC 26 CHC 30 HCV-positive cirrhosis 8 HCC            blood     Turkey    NA                                                                                                   up                                    NA                                25391771[@b81]                   NA
  miR-30c-5p     miR-30c-5p             28 HC 26 CHC 30 HCV-positive cirrhosis 8 HCC            blood     Turkey    1.HCV-positive cirrhosis2.interferon-beta therapy                                                    up                                    NA                                25391771[@b81]                   NA
  miR-331-3p     miR-331-3p                         40 HC 95 BLD 103 HCC                        serum      China    1.proliferation2.metastasis                                                                          up                                   0.89                               25903466[@b61]                   PH
  miR-34a        miR-34a-5p                    42 HC 125 HCV-CLD 112 HCV-HCC                    blood      Egypt    child stage and BCLC score                                                                           up              HCV-HCC from HC 0.98 HCV-HCC from HCV-CLD 0.67          26352740[@b42]                   NA
  miR-375          miR-375                             156 HC 78 HCC                            serum      China    tumor suppressor                                                                                    down                                 0.637                               25618599[@b58]                   NA
  miR-375          miR-375                     210 HC 135 HBV 48 HCV 120 HCC                    serum      China    NA                                                                                                   up                                   0.96                               21098710[@b140]                  NA
  miR-433-3p     miR-433-3p                        173 HC 233 LC 261 HCC                        serum      China    NA                                                                                                   up               0.887(training sets) 0.879(validation sets)            25238238[@b86]                   NA
  miR-483-5p     miR-483-5p                             69 HC 69 HCC                            serum     America   anti-apoptotic oncogene                                                                              up                            HCC from HC 0.827                         24127413[@b40]                   NA
  miR-885-5p     miR-885-5p             24 HC 23 CHB 26 LC 17 GC 9 ICC 6 FNH 46 HCC             serum      China    cholesterol reverse transport                                                                        up                                  0.904                               20815808[@b111]                  NA
  let-7b          let-7b-5p                         15 HC 30 DN 120 HCC                         serum      China    tumor suppressor                                                                                     up                                  0.645                               26264553[@b44]                   NA
  miR-203        miR-203a-3p   10 HC 30 non-cirrhotic HCV 25 HCV-related cirrhosis 23 HCV-HCC   serum      Egypt    1.tumor-suppressive2.angiogenesis                                                                   down                         HCC from non-HCC 0.76                       27268654[@b141]                  NA
  miR-885-5p     miR-885-5p                      192 HCC 96 LC 96 CHC 95 HC                     serum      Egypt    1.onco-miR2.liver injury                                                                             up                    HCC from HC 0.63 HCC from LC 0.775                27271989[@b120]                 ISRE
  miR-122        miR-122-5p                      193 HCC 96 LC 96 CHC 95 HC                     serum      Egypt    1.tumor suppressor2.regulate lipid and cholesterol metabolism                                        up                   HCC from HC 0.617 HCC from LC 0.617                27271989[@b120]                ADAM17
  miR-29b        miR-29b-3p                      194 HCC 96 LC 96 CHC 95 HC                     serum      Egypt    tumor suppressor                                                                                    down                           HCC from HC 0.766                         27271989[@b120]                  NA
  miR-221        miR-221-3p                      195 HCC 96 LC 96 CHC 95 HC                     serum      Egypt    1.onco-miR2.apoptosis                                                                                up                            HCC from LC 0.702                         27271989[@b120]         CDKN1B/p27CDKN1C/p57
  miR-181b       miR-181b-5p                     196 HCC 96 LC 96 CHC 95 HC                     serum      Egypt    1.onco-miR2.migration and invasion                                                                   up                            HCC from LC 0.679                         27271989[@b120]                TIMP3
  miR-22          miR-22-3p                      197 HCC 96 LC 96 CHC 95 HC                     serum      Egypt    tumor suppressor                                                                                    down                           HCC from CHC 0.586                        27271989[@b120]                HDAC4
  miR-199a-3p    miR-199a-3p                     198 HCC 96 LC 96 CHC 95 HC                     serum      Egypt    tumor suppressor                                                                                    down                            HCC from CHC 0.7                         27271989[@b120]                 mTOR
  miR-125b       miR-125b-5p                 56 HC 63 CHB 59 HBV-LC 64 HBV-HCC                  plasma     China    1.tumor suppressor2.migration and invasion3.cellular proliferation and cell cycle progression       down                         HBV-HCC from HC 0.891                       27152955[@b121]                LIN28B
  miR-96          miR-96-5p                     104 HCC 100 CHB 90 LC 120 HC                    serum      China    1.onco-miR2.migration and invasion                                                                   up                            HCC from CHB 0.803                        26770453[@b142]                  NA
  miR-126        miR-126-3p                          28 HC 20 LC 59 HCC                         plasma     India    NA                                                                                                   up         low AFP HCC from non-HCC 0.765 low AFP HCC from LC 0.643     26756996[@b143]   APAF1, APC2, VEGFA, IRS1, CDKN2A
  miR-224        miR-224-5p                      26 HCC 22 LC 23 CHB 22 HC                      serum      China    1.migration and invasion2.suppress apoptosis                                                         up                                   0.88                               26724963[@b144]                  NA

Abbreviations and note: HC: healthy controls; CHB: patients with chronic type B hepatitis; CLD: chronic liver disease; HCV-CLD: non-malignant HCV-associated CLD patients; DN: chronic hepatitis B patients with pathologically proven DN; ICC: intrahepatic cholangiocellular carcinoma; LC: liver cirrhosis; HCV: hepatitis C virus HBV: hepatitis B virus; NA: not available; 1: upregulated in the HBV-LC group; 2: combined classifier (AFP and miRNA-122a); 3; combination of plasma miRNA-139 with serum AFP; 4: combined miR-15b and miR-130b; 5: Combined serum alpha-fetoprotein (AFP) and miR-24-3p.

###### Prognostic biomarkers in tissues for hepatocellular carcinoma.

  Reported ID    Offical ID                 Sample                 Ethnicity  Features                                                                                                                                                              Expression        PMID                                 Validated Targets
  ------------- ------------- ----------------------------------- ----------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ----------------- -------------------------------------------------------------------
  miR-101        miR-101-3p            20 HC 25 HBV-HCC              China    1.HBsAg, HBV DNA level and tumor size                                                                                                                                     up       24260081[@b112]                                  NA
  miR-101        miR-101-3p                 130 HCC                  China    tumor suppressor                                                                                                                                                         down      23178713[@b99]                                  SOX9
  miR-101        miR-101-3p    30 HC 79 CHB 61 HBV-LC 67 HBV-HCC     China    1.inhibit HCC cell proliferation2.tumor suppressor                                                                                                                        up       24971953[@b38]                                   NA
  miR-106b       miR-106b-5p                104 HCC                  China    1.tumor size2. vascular invasion3. proliferation4. anchorage-independent growth of HCC cells5.metastasis                                                                  up       25466449[@b64]                                   NA
  miR-122        miR-122-5p                 60 HCC                   China    1.tumor suppressor2.maintenance of normal physiological metabolism                                                                                                       down      26252254[@b100]                                 PKM2
  miR-125b       miR-125b-5p                49 HCC                   China    tumor suppressor                                                                                                                                                         down      24811246[@b101]                                Eif5a2
  miR-1269        miR-1269a                 95 HCC                   China    1.tumor nodes2.portal vein tumor embolus3.vaso-invasion4.tumor capsular infiltration5.expression of MTDH6.onco-miR7.carcinogenesis, metastasis and invasion of HCC        up       25785048[@b72]    AGAP1, AGK, BPTF, C16orf74, DACT1, LIX1L, RBMS3, ZNF706 and BMPER
  miR-128-3p     miR-128-3p                 72 HCC                   China    1.suppress proliferation2.suppress metastasis                                                                                                                            down      25962360[@b73]                             PIK3R1 PI3K/AKT
  miR-130a       miR-130a-3p                102 HCC                  China    1.gender, HBsAgstatus, tumor size, and TNM stage2.tumor suppressor                                                                                                       down      25218269[@b102]                                  NA
  miR-137          miR-137                  136 HCC                  China    1.vein invasion2.distant metastasis3.inhibition promotes HCC cell growth                                                                                                 down      24970808[@b35]                                  AKT2
  miR-146a       miR-146a-5p                85 HCC                   China    tumor suppressor                                                                                                                                                         down      24172202[@b103]                                 ROCK1
  miR-155        miR-155-5p                 100 HCC                  China    1.metastasis2.inhibits apoptosis                                                                                                                                          up       23863669[@b45]                                   NA
  miR-155        miR-155-5p                 216 HCC                  China    onco-miR                                                                                                                                                                  up       22629365[@b108]                                  NA
  miR-17-5p       miR-17-5p                 120 HCC                  China    regulating proliferation and migration                                                                                                                                    up       22583011[@b65]                             p38 MAPK-HSP27
  miR-182        miR-182-5p                 81 HCC                   China    1.onco-miR2.motility and invasiveness                                                                                                                                     up       25813403[@b66]                                  FOXO1
  miR-182        miR-182-5p                 86 HCC                   China    intrahepatic metastasis                                                                                                                                                   up       22681717[@b67]                                  MTSS1
  miR-183        miR-183-5p                 81 HCC                   China    1.onco-miR2.motility and invasiveness                                                                                                                                     up       25813403[@b66]                                  FOXO1
  miR-185        miR-185-5p              41 NTR 54 TR                China    1.suppress the tumor cell growth2.suppress invasive                                                                                                                      down      23648054[@b36]                                   NA
  miR-188-5p     miR-188-5p                 250 HCC                  China    1.suppress tumor cell proliferation2.suppress metastasis                                                                                                                 down      25998163[@b74]                                  FGF5
  miR-18b        miR-18b-5p                 110 HCC                  Japan    1.proliferation2.loss of cell adhesion ability                                                                                                                            up       23496901[@b52]                                 TNRC6B
  miR-199a-5p    miR-199a-5p                120 HCC                  China    1.Negatively Associated With Malignancies2.Regulates Glycolysis3.Lactate Production                                                                                      down      26054020[@b145]                             Hexokinase 2
  miR-206          miR-206                  147 HCC                  China    1.suppresses cell proliferation2.promotes apoptosis.                                                                                                                     down      25513086[@b46]                                   NA
  miR-21          miR-21-5p           50 HC 30 CH 136 HCC            Japan    NA                                                                                                                                                                       down      21749846[@b110]                                  NA
  miR-21          miR-21-5p                 112 HCC                  China    1.tumor differentiation2.TNM stage3.vein invasion                                                                                                                         up       26261620[@b68]                                   NA
  miR-21          miR-21-5p                 119 HCC                  China    1.tumorinvasion, metastasis and prognosis2.promote cell proliferation and invasion3.inhibits cell apoptosis                                                               up       25150373[@b47]                                   NA
  miR-21          miR-21-5p                 74 ICC                   China    intrahepatic cholangiocarcinoma proliferation and growth                                                                                                                  up       25803229[@b56]                             PTPN14 and PTEN
  miR-212        miR-212-3p                 86 HCC                   China    1.inhibited cell proliferation2.induced apoptosis                                                                                                                        down      26347321[@b48]                                  FOXA1
  miR-214        miR-214-3p                 65 HCC                   China    tumor suppressor                                                                                                                                                         down      23962428[@b104]                                FGFR-1
  miR-25          miR-25-3p                 96 HCC                   Iran     1.TNM stage2.suppress proliferation3.suppress migration                                                                                                                   up       26209296[@b69]                                   NA
  miR-26a        miR-26a-5p                 120 HCC                  China    1.Cell Cycle2.angiogenesis                                                                                                                                                up       24259426[@b84]                             CDK6, cyclin D1
  miR-26a        miR-26a-5p                 130 HCC                  China    1.suppress the tumor cell growth2.suppress invasive                                                                                                                      down      23389848[@b37]                           interleukin-6-Stat3
  miR-331-3p     miR-331-3p                 457 HCC                  China    1.Promotes Proliferation2.Metastasis                                                                                                                                      up       24825302[@b70]                 Leucine-Rich Repeat Protein Phosphatase
  miR-34a        miR-34a-5p                 120 HCC                  China    1.tumor size2.higher serum AFP level                                                                                                                                     down      25596083[@b113]                                  NA
  miR-424        miR-424-5p                 96 HCC                   China    suppressed proliferation                                                                                                                                                 down      26315541[@b87]                     pRb-E2F pathway, Akt3 and E2F3
  miR-503        miR-503-5p                 20 HCC                   China    suppress metastasis                                                                                                                                                      down      26163260[@b75]                                  PRMT1
  miR-744        miR-744-5p                 96 HCC                   China    1.tumour suppressor2.tumor malignancy3.tumor cell proliferation4.invasion and migration5.HCC recurrence6.poor prognosis                                                  down      25543521[@b76]                                   NA
  miR-9           miR-9-5p                  200 HCC                  China    1.tumour suppressor2.tumor stage3.venous infiltration                                                                                                                     up       25552204[@b71]                                   NA
  miR-96          miR-96-5p                 81 HCC                   China    1.onco-miR2.motility and invasiveness                                                                                                                                     up       25813403[@b66]                                  FOXO1
  miR-125a       miR-125a-5p                80 HCC                   China    1.Proliferation 2.Metastasis                                                                                                                                             down      22768249[@b146]                            MMP11 and VEGF
  miR-99a        miR-99a-5p                 142 HCC                  China    tumor suppressor                                                                                                                                                         down      21878637[@b147]                                  NA

Abbreviations and note: HC: healthy controls; CHB: patients with chronic type B hepatitis; CLD: chronic liver disease; HCV-CLD: non-malignant HCV-associated CLD patients; DN: chronic hepatitis B patients with pathologically proven DN; ICC: intrahepatic cholangiocellular carcinoma; LC: liver cirrhosis; HCV: hepatitis C virus; HBV: hepatitis B virus; CH: chronic hepatitis; TR: treated recurrence group; NTR: none treated recurrence group; NA: not available.

###### Prognostic biomarkers in blood for hepatocellular carcinoma.

  Reported ID    Offical ID                 Sample                 Source    Ethnicity   Features                                                                                                                                                                         Expression        PMID         Validated Targets
  ------------- ------------- ----------------------------------- -------- ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ----------------- -------------------
  miR-1           miR-1-3p               54 LC 195 HCC             serum      Germany    1.differentiation2.tumor suppressor                                                                                                                                                  up       23810247[@b91]           NA
  miR-101        miR-101-3p            20 HC 25 HBV-HCC            serum       China     1.HBsAg, HBV DNA level and tumor size                                                                                                                                                up       24260081[@b112]          NA
  miR-101        miR-101-3p    30 HC 79 CHB 61 HBV-LC 67 HBV-HCC   serum       China     1.inhibit HCC cell proliferation2.tumor suppressor                                                                                                                                   up       24971953[@b38]           NA
  miR-122        miR-122-5p                 122 HCC                blood       China     1.tumor suppressor2.proliferation3.differentiation4.regulation of cholesterol and lipid metabolisms5.stability and propagation of hepatitis C virus and hepatitis B infection        up       25636448[@b77]           NA
  miR-122        miR-122-5p                 120 HCC                plasma   South Korea  1.hepatic necroinflammatory activity2.cell death3.tumor suppressor                                                                                                                   up       26129878[@b49]           NA
  miR-122        miR-122-5p              54 LC 195 HCC             serum      Germany    1.liver transaminases2.MELD score                                                                                                                                                   down      23810247[@b91]           NA
  miR-128-2       miR-128-2           20 HCC 20 HCC(PVTT)          serum       China     onco-miR                                                                                                                                                                             up       25642945[@b109]          NA
  miR-150        miR-150-5p         120 HC 110 CHB 120 HCC         serum       China     1.tumor suppressor2. metastasis3.BCLC stage4.advanced TNM stages                                                                                                                    down      26215970[@b60]           NA
  miR-16          miR-16-5p              60 HC 90 HCC              serum       China     1.tumor size2.liver dysfunction and coagulation defect                                                                                                                              down      24697119[@b114]          NA
  miR-16          miR-16-5p              40 HCV 40 HCC             serum       Egypt     1.apoptosis2.bilirubin                                                                                                                                                              down      26133725[@b50]           NA
  miR-17-5p       miR-17-5p                 96 HCC                 blood       China     1.metastasis2.TNM stage                                                                                                                                                              up       23108086[@b78]           NA
  miR-182        miR-182-5p          40 HC 95 BLD 103 HCC          serum       China     metastasis                                                                                                                                                                           up       25903466[@b61]        TP53INP1
  miR-199a       miR-199a-5p             40 HCV 40 HCC             serum       Egypt     tumor size                                                                                                                                                                          down      26133725[@b50]           NA
  miR-203a       miR-203a-3p          90 HCV 152 HCV-HCC           serum       China     tumor suppressor                                                                                                                                                                    down      26210453[@b105]         Snal2
  miR-21          miR-21-5p           50 HC 30 CH 136 HCC          serum       Japan     NA                                                                                                                                                                                  down      21749846[@b110]          NA
  miR-21          miR-21-5p                 74 ICC                 serum       China     intrahepatic cholangiocarcinoma proliferation and growth                                                                                                                             up       25803229[@b56]     PTPN14 and PTEN
  miR-21          miR-21-5p              60 HC 90 HCC              serum       China     liver injury                                                                                                                                                                        down      24697119[@b114]          NA
  miR-24-3p       miR-24-3p           46 HC 31 CLD 84 HCC          serum       China     vascular invasion                                                                                                                                                                    up       25129312[@b63]           NA
  miR-30c        miR-30c-5p           90 HCV 152 HCV-HCC           serum       China     tumor suppressor                                                                                                                                                                    down      26210453[@b105]          EMT
  miR-331-3p     miR-331-3p          40 HC 95 BLD 103 HCC          serum       China     1.proliferation2.metastasis                                                                                                                                                          up       25903466[@b61]           PH
  miR-335        miR-335-5p       125 HC 125 HCV/HBV 125 HCC       serum       China     response to TACE and clinical outcome                                                                                                                                               down      26305026[@b148]          NA
  let-7f          let-7f-5p              60 HC 90 HCC              serum       China     1.tumor size2.early recurrence                                                                                                                                                      down      24697119[@b114]          NA

Abbreviations and note: PVTT: portal vein tumor thrombosis; LC: liver cirrhosis; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; HC: healthy controls; CHB: patients with chronic type B hepatitis; BLD: benign liver diseases; ICC: intrahepatic cholangiocellular carcinoma; CH: chronic hepatitis; NA: not available.

###### Therapeutic biomarkers for hepatocellular carcinoma.

  Reported ID    Offical ID       Sample      Source    Ethnicity   Features                                                       Expression        PMID                    Validated Targets
  ------------- ------------- -------------- -------- ------------- ------------------------------------------------------------- ------------ ----------------- -----------------------------------------
  miR-335        miR-335-5p       62 HCC      tissue      China     inhibit the proliferation and migration invasion                  down      25804796[@b149]                    ROCK1
  miR-192        miR-192-5p    59 HC 59 HCC   tissue   South Korea  increase tumor cell migration and invasion                        down      25065598[@b150]                     NA
  miR-224        miR-224-5p    9 HC 10 HCC    tissue      China     1.cell proliferation s2. migration3.invasion4.anti-apoptosi        up       24789420[@b39]                     CD40
  miR-214        miR-214-3p    9 HC 10 HCC    tissue      China     tumor suppressor                                                  down      24789420[@b39]             EZH2, CTNNB1 and CDH1
  miR-148a       miR-148a-3p      19 HCC      tissue      China     onco-miR                                                           up       22496917[@b106]                     NA
  miR-206          miR-206       147 HCC      tissue      China     1\. suppress cell proliferation2.promote apoptosis.               down      25513086[@b46]                      NA
  miR-331-3p     miR-331-3p      457 HCC      tissue      China     1\. promote proliferation2. metastasis                             up       24825302[@b70]    Leucine-Rich Repeat Protein Phosphatase
  miR-26a        miR-26a-5p      120 HCC      tissue      China     1\. cell Cycle2. angiogenesis                                      up       24259426[@b84]                CDK6, cyclin D1
  miR-26a        miR-26a-5p      130 HCC      tissue      China     1\. suppress the tumor cell growth2. suppress invasive            down      23389848[@b37]              interleukin-6-Stat3

Abbreviations and note: HC: healthy controls; NA: not available.
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